"10.1371_journal.pone.0075550","plos one","2013-10-16T00:00:00Z","Yared Santa-Ana-Tellez; Aukje K Mantel-Teeuwisse; Anahi Dreser; Hubert G M Leufkens; Veronika J Wirtz","WHO Collaborating Centre for Pharmaceutical Policy & Regulation, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands; Center for Health Systems Research, National Institute of Public Health, Cuernavaca, Mexico; Center for Global Health and Development, Boston University, Boston, Massachusetts, United States of America","Analyzed the data: YS VJW AKM. Wrote the paper: YS AKM VJW AD HGML.","The WHO Collaborating Centre for Pharmaceutical Policy & Regulation receives no direct funding or donations from private parties, including the pharma industry. Research funding from public-private partnerships, e.g. IMI, TI Pharma (www.tipharma.nl) is accepted under the condition that no company-specific product or company-related study is conducted. The Centre has received unrestricted research funding from public sources, e.g. The Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), EU 7th Framework Program (FP7), the Dutch Medicines Evaluation Board (MEB), and the Dutch Ministry of Health.","2013","10","Yared Santa-Ana-Tellez","YSAT",5,TRUE,NA,NA,3,5,TRUE,TRUE,FALSE,0,NA,FALSE
